Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $92.50 USD
Change Today +0.32 / 0.35%
Volume 2.0M
SYK On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

stryker corp (SYK) Snapshot

Open
$91.54
Previous Close
$92.18
Day High
$92.79
Day Low
$91.17
52 Week High
12/23/14 - $98.24
52 Week Low
04/28/14 - $75.78
Market Cap
35.1B
Average Volume 10 Days
1.2M
EPS TTM
$4.34
Shares Outstanding
379.0M
EX-Date
03/27/15
P/E TM
21.3x
Dividend
$1.38
Dividend Yield
1.41%
Current Stock Chart for STRYKER CORP (SYK)

stryker corp (SYK) Details

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment offers implants used in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment provides surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, and reprocessed and remanufactured medical devices, as well as other medical device products for use in various medical specialties. The Neurotechnology and Spine segment offers neurosurgical and neurovascular devices that include products used for minimally invasive endovascular techniques; products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also develops, manufactures, and markets spinal implant products, including cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company markets its products to doctors, hospitals, and other healthcare facilities in the United States; and sells its products through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 100 countries internationally. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

26,000 Employees
Last Reported Date: 02/12/15
Founded in 1941

stryker corp (SYK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President
Total Annual Compensation: $536.7K
Group President of Medsurg & Neurotechnology
Total Annual Compensation: $568.5K
Group President of International
Total Annual Compensation: $526.7K
Group President of Orthopaedics
Total Annual Compensation: $513.3K
Compensation as of Fiscal Year 2014.

stryker corp (SYK) Key Developments

Stryker Spine and Stryker Trauma and Extremities to Launch Next Generation Viable Bone Matrix at the American Academy of Orthopaedic Surgeons

Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th. From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic. It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities. With the introduction of BIO4, Stryker now plays in the growing $199 million Cellular Allograft Market.

Stryker Corporation Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 01:00 PM

Stryker Corporation Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 01:00 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States.

Smith & Nephew Falls On Bid Rumours

Smith & Nephew plc (LSE:SN.), which only a day earlier had been puffed up by bid speculation, suffered the heaviest fall in the FTSE 100 after takeover hopes began to evaporate. Although it was Johnson & Johnson (NYSE:JNJ) that was rumored to be weighing an approach for the FTSE 100 company, traders have long considered a bid from Stryker Corporation (NYSE:SYK) as more likely.Takeover Panel rules prohibited the company from making a bid for six months but those restrictions lifted last November and ever since there has been growing speculation that Stryker would revive its interest.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYK:US $92.50 USD +0.32

SYK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.91 USD -0.24
Becton Dickinson and Co $141.53 USD -0.86
Boston Scientific Corp $18.40 USD +0.24
Ecolab Inc $115.20 USD -1.63
Kimberly-Clark Corp $106.78 USD -0.90
View Industry Companies
 

Industry Analysis

SYK

Industry Average

Valuation SYK Industry Range
Price/Earnings 68.8x
Price/Sales 3.6x
Price/Book 4.1x
Price/Cash Flow 49.9x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRYKER CORP, please visit www.strykercorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.